The SNAP 101 Double-Blind, Placebo/Active-Controlled, Safety, Pharmacokinetic, and Pharmacodynamic Study of INP105 (Nasal Olanzapine) in Healthy Adults
Current Language EN
English English Türkçe Türkçe Español Español Português Português Pусский Pусский Filipino Filipino Tiếng Việt Tiếng Việt हिन्दी हिन्दी العربية العربية বাংলা বাংলা Deutsch Deutsch 中文 中文

The SNAP 101 Double-Blind, Placebo/Active-Controlled, Safety, Pharmacokinetic, and Pharmacodynamic Study of INP105 (Nasal Olanzapine) in Healthy Adults

Stephen B. Shrewsbury;Jasna Hocevar-Trnka;Kelsey H. Satterly;Karen L. Craig;Jason D. Lickliter;John Hoekman;
the journal of clinical psychiatry 2020 Vol. 81 pp. 0-0
78
shrewsbury2020thethe

Abstract

Aside from intramuscular injection, few rapidly acting pharmacotherapeutic treatments are available for acute agitation. This study examined the safety and tolerability of INP105, a drug-device combination product that allows nasal delivery of olanzapine.

Keywords

keywords:antipsychotics; keywords:bipolar disorder; focus psychosis; jcp; j clin psychiatry:nlm:journal article; j clin psychiatry:portico:research-article

Access

URL:
http://www.psychiatrist.com/JCP/article/Pages/2020...

Citation

ID: 119884
Ref Key: shrewsbury2020thethe
Use this key to autocite in SciMatic or Thesis Manager

References

References

No Bibliography

Blockchain Verification

Account:
NFT Contract Address:
0x95644003c57E6F55A65596E3D9Eac6813e3566dA
Article ID:
119884
Unique Identifier:
Network:
Scimatic Chain (ID: 481)
Blockchain Readiness Checklist
Authors
Abstract
Journal Name
Year
Title
5/5
Creates 1,000,000 NFT tokens for this article
Token Features:
  • ERC-1155 Standard NFT
  • 1 Million Supply per Article
  • Transferable via MetaMask
  • Permanent Blockchain Record
Blockchain QR Code
Scan with Saymatik Web3.0 Wallet
Gas fees required in SCI Coins
Buy SCI

Saymatik Web3.0 Wallet

Google Play
App Store